UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000033092
Receipt number R000037734
Scientific Title Evaluation of a newly developed scoring system for detection of early pancreatic cancer: A prospective multi center study.
Date of disclosure of the study information 2018/06/21
Last modified on 2019/11/01 15:48:40

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Evaluation of a newly developed scoring system for detection of early pancreatic cancer: A prospective multi center study.

Acronym

A newly developed scoring system for detection of early pancreatic cancer.

Scientific Title

Evaluation of a newly developed scoring system for detection of early pancreatic cancer: A prospective multi center study.

Scientific Title:Acronym

A newly developed scoring system for detection of early pancreatic cancer.

Region

Japan


Condition

Condition

Pancreatic cancer

Classification by specialty

Hepato-biliary-pancreatic medicine

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

Evaluation of newly developed scoring system for detection of early pancreatic cancer.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Detection of pancreatic cancer and early pancreatic cancer less than 10 mm in diameter.

Key secondary outcomes



Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Self control

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Diagnosis

Type of intervention

Other

Interventions/Control_1

Perform of Endoscopic ultrasound
Perform of Endoscopic ultrasound according to cases

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

18 years-old <=

Age-upper limit

95 years-old >=

Gender

Male and Female

Key inclusion criteria

The patients with 3 risk factors or more, sporadic family history of pancreatic cancer, diabetes, alcohol 37.5g/day, smoking, obesity, stomach symptoms or back pain, weight loss, diabetes exacerbation, and increase in pancreatic enzyme.
The patients with 1 risk factor or more, new onset of diabetes, familial pancreatic cancer, jaundice, increase in tumor markers, chronic pancreatitis, intraepithelial pancreatic mucinous neoplasm, pancreatic cyst, hereditary pancreatic cancer syndrome, hereditary pancreatitis, and pancreatic duct dilation.

Key exclusion criteria

Cases in which pancreatic cancer is strongly suspected by other image modality before screening.
Cases in which pancreatic screening had been already performed and followed.
When informed consent can not be obtained.

Target sample size

3500


Research contact person

Name of lead principal investigator

1st name Ryota
Middle name
Last name Sagami

Organization

New Tokyo Hospital

Division name

Department of Gastroenterology

Zip code

2702232

Address

1271 Wanagaya, Matsudo Chiba, Japan

TEL

0477118700

Email

sagami1985@yahoo.co.jp


Public contact

Name of contact person

1st name Ryota
Middle name
Last name Sagami

Organization

New Tokyo Hospital

Division name

Department of Gastroenterology

Zip code

2702232

Address

1271 Wanagaya, Matsudo Chiba, Japan

TEL

0477118700

Homepage URL


Email

sagami1985@yahoo.co.jp


Sponsor or person

Institute

New Tokyo Hospital

Institute

Department

Personal name



Funding Source

Organization

None

Organization

Division

Category of Funding Organization

Other

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

New Tokyo Hospital

Address

1271 Wanagaya, Matsudo Chiba, Japan

Tel

0477118700

Email

sagami1985@yahoo.co.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2018 Year 06 Month 21 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2018 Year 11 Month 09 Day

Date of IRB

2018 Year 02 Month 25 Day

Anticipated trial start date

2018 Year 06 Month 21 Day

Last follow-up date

2019 Year 11 Month 01 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2018 Year 06 Month 21 Day

Last modified on

2019 Year 11 Month 01 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000037734